An amendment to this paper has been published and can be accessed via the original article.
Gackler A., Schonermarck U., Dobronravov V., La Manna G., Denker A., Liu P., et al. (2021). Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis (BMC Nephrology, (2021), 22, 1, (5), 10.1186/s12882-020-02190-0). BMC NEPHROLOGY, 22, 1-1 [10.1186/s12882-021-02242-z].
Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis (BMC Nephrology, (2021), 22, 1, (5), 10.1186/s12882-020-02190-0)
La Manna G.;
2021
Abstract
An amendment to this paper has been published and can be accessed via the original article.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Gäckler A et al_BMC Nephrology 2021_correction.pdf
accesso aperto
Descrizione: Gäckler A et al_BMC Nephrology 2021_correction
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
193 kB
Formato
Adobe PDF
|
193 kB | Adobe PDF | Visualizza/Apri |
|
Supplementary materials.zip
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per accesso libero gratuito
Dimensione
686.46 kB
Formato
Zip File
|
686.46 kB | Zip File | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
